The mechanism of action includes several key effects: they stimulate insulin secretion from pancreatic beta cells in a glucose-dependent manner, suppress glucagon release (which reduces hepatic glucose production), slow gastric emptying, and act on appetite centres in the brain to promote satiety and reduce food intake
GLP-1 medication does not cause eating disorders in the way that a virus causes an infection
While numerous proof-of-concept candidate molecules have been disclosed ( and Zepbound ) ( ex vivo finding, the GIPR monoagonist LY3537021 reduced body weight by ~4.1% over 8 weeks in patients with T2D (n = 18) ( 2.2 GIPR agonism serves to reduce GLP-1R mediated GI AEs in the clinic Treatment with GLP-1R agonists can drive nausea, diarrhea, vomiting, and constipation, which often results in discontinuation of treatment (6-10% of patients) or reduction in dose (~15% of patients) ( It has been hypothesized that the deleterious, nauseating effects of GLP-1R agonists and the beneficial, food-intake reducing effects are inextricably linked
I find this component of Modere Curb particularly appealing for those who aim to maintain calorie control by potentially reducing the urge to snack between meals
GLP-1s help to stimulate insulin release and reduce glucagon production
La berberina puede interactuar con varios medicamentos (como ciclosporina, estatinas y frmacos metabolizados por CYP3A4), est contraindicada durante el embarazo y la lactancia, y puede causar efectos gastrointestinales y, raramente, hepatotoxicidad
